SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares

The latest update is out from SynAct Pharma AB ( (SE:SYNACT) ).

SynAct Pharma AB has repurchased 212,307 of its own shares under a share buyback program of up to SEK 5 million authorized by its board and shareholders, with transactions executed on Nasdaq Stockholm between 12 January and 12 February 2026. The buybacks, carried out by Mangold Fondkommission AB and now representing 212,307 treasury shares out of a total 53,330,243 outstanding, may signal management’s confidence in the company’s valuation and capital position while modestly enhancing earnings per share for existing investors.

The most recent analyst rating on (SE:SYNACT) stock is a Hold with a SEK22.00 price target. To see the full list of analyst forecasts on SynAct Pharma AB stock, see the SE:SYNACT Stock Forecast page.

More about SynAct Pharma AB

SynAct Pharma AB is a clinical-stage biotechnology company listed on Nasdaq Stockholm that focuses on resolving inflammation by selectively activating the melanocortin system. It develops a portfolio of oral and injectable selective melanocortin agonists designed to induce anti-inflammatory and inflammation-resolving activity, aiming to help patients restore immune balance and manage inflammatory conditions.

Average Trading Volume: 135,123

Technical Sentiment Signal: Sell

Current Market Cap: SEK993M

See more data about SYNACT stock on TipRanks’ Stock Analysis page.